Abstract
Despite an increase in global research on the subject of Pemphigus, which seriously affects patient health and quality of life, there is no bibliometric research on this subject in literature to date. The aim of this study was to conduct a holistic analysis of scientific articles published on Pemphigus, using bibliometric methods. Articles published on the subject of Pemphigus between 1980 and 2021 were downloaded from the web of science (WoS) database and analyzed using various statistical methods. To determine trend subjects, collaboration between countries, and the most effective studies with citation analyses, visual network maps were obtained with bibliometric analyses. A total of 3034 articles were analyzed. The 3 countries making the greatest contribution to literature were the USA (n:831, 27.3%), Japan (n:402, 13.2%), and Germany (n:221, 7.2%). The 3 most active institutions were Keio University (n:163, 5.3%), Kurume University (n:130, 4.2%) and Tel Aviv University (n:107, 3.5%). The 3 journals publishing the most articles were the British Journal of Dermatology (n: 88), Journal of the American Academy of Dermatology (n:171) and the Journal of Investigative Dermatology (n:143). The 3 leading journals according to the mean number of citations (NC) per article (citation count: CC) were the New England Journal of Medicine (CC:246), the Lancet (CC:143) and the Journal of Cell Biology (CC:133). The author with the most articles published was Hashimoto Takashi (n.168, 5.5%). As a result of cluster analysis, it was seen that 9 different main clusters had been studied on Pemphigus subjects to date (1: desmoglein, 2: paraneoplastic Pemphigus (PNP) – Pemphigus types-desmosome, 3: desmoglein 1 ve 3-autoimmunity, 4: treatment-rituximab, 5: acantholysis-apoptosis, 6: quality of life-remission-relapse, 7: autoantibodies, 8: epidemiology-mortality, 9: corticosteroids). The most commonly studied subjects were determined to be pemphigus vulgaris (PV), pemphigus foliaceus (PF), autoimmunity, rituximab, PNP, desmoglein (desmoglein3-desmoglein1), autoantibodies, acantholysis, autoantibody, treatment, autoimmune disease, desmosome, ELISA, and immunofluorescence. The primary trending topic was rituximab drug, which is used in the treatment of Pemphigus. The other most studied trend topics were azathioprine drug used in treatment, intravenous immunoglobulin treatment, quality of life, mortality rates, Pemphigus herpetiformis, and wound healing.
Keywords: bibliometric analysis, paraneoplastic pemphigus, Pemphigus foliaceus, Pemphigus vulgaris, trends
1. Introduction
Pemphigus is an uncommon, severe, autoimmune disease affecting the skin and mucosa, which manifests with fluid-filled blisters.[1–4] IgG autoantibodies are characteristically elevated against desmoglein 1 and desmoglein 3, which are cell-cell adhesive molecules found in desmosomes.[3] Pemphigus can be classified into 3 main sub-forms: Pemphigus vulgaris (PV), Pemphigus foliaceus (PF), and paraneoplastic Pemphigus (PNP).[3]
In PV, blisters develop immediately over the basal cell layer and are associated with autoantibodies against desmoglein 3, which is a keratinocyte cell surface adhesive molecule. PV is the most common form of the disorder, and the wounds generally start in the mouth and make eating difficult. Although PV can emerge at any age, it is seen most often between the ages of 40 and 60 years.[5] In PF, the blisters are higher immediately below the stratum corneum in the epidermis and are associated with desmoglein 1, which is another cell surface adhesive molecule.[2] Of the 3 types, PF is the least severe. PF usually starts on the scalp, and is characterized by scabbed wounds which can move to the chest, back and face. Intra-oral wounds do not form, it is not as painful as PV, and are often confused with dermatitis or eczema.[5] The phenotype of PNP is typically characterized by blisters in the deep epithelial layers and interface dermatitis, and originates from a combination of humoral and cellular reactions.[3] PNP is the least frequently seen and most severe Pemphigus type. This disorder is generally a complication of cancer, primarily lymphoma and Castleman disease. It may develop before diagnosis of the tumor, with painful sores in the mouth, on the lips, and in the esophagus. This disease process in Pemphigus usually includes the lungs and causes constrictive bronchiolitis.[6]
The disease is diagnosed from clinical symptoms (loose blisters and erosions on the skin and oral mucosa), and histological and immunochemical tests.[2,3] Skin lesions caused by Pemphigus can led to fatal infections, and therefore treatment is extremely important. Pemphigus, which is usually fatal when not treated, is generally treated with topical, oral, or intralesional corticosteroids. Other treatment options include immunosuppressive agents (micophenolate mofetil and azathioprine), intravenous immunoglobulin (IVIG), and adjuvant treatments including plasmapheresis and immunoadsorption.[2,3,7] Biological agents such as rituximab, which is an anti-CD20 antibody, have been found to improve severely resistant PV cases and have been approved as first-stage treatment for moderate and severe PV in Europe and the USA.[3,4,8,9]
Pemphigus is a rarely seen disease and the global incidence varies significantly. In most populations, PF is less common than PV.[10] In Europe, the USA, and Japan, PV is the most common subtype, whereas PF is the endemic form in South America and North Africa, and thus the most often seen subtype.[11] Although all ethnicities can be affected by the disease, it is most common in those of Mediterranean and Jewish origin.[2] PV incidence has been reported at varying rates; as 0.7 (0.6–0.8) per 100,000 per year in the UK,[12] 0.5 per million in Germany, 8 per million in Greece, 16.1 per 100,000 in Israel, 0.076 per 100,000 in Finland, and 1.61 per 100,000 in Jerusalem.[10,13–15] The incidence of PNP is unknown but it is lower than for PV and PF.[3]
Bibliometry is the analysis of scientific publications using various statistical methods.[16–18] Due to bibliometric studies, researchers can have greater knowledge of the literature by reading the summarized findings of thousands of studies.[16] By showing the previous and current subjects of research, bibliometric studies can also offer ideas for new studies.[17] In parallel with the increasing number of publications in literature, bibliometric research has been conducted on many subjects in the field of medicine.[16–18]
As a result of a meta-analysis and systematic examination of 16 studies from 8 different countries, it was reported that health-related quality of life was seriously diminished in patients with Pemphigus and the decrease in health-related quality of life was clearly associated with high disease activity, anxiety and depression.[19] Despite the increase in the number of studies worldwide on the subject of Pemphigus, which seriously affects patient health and QoL, there has been no bibliometric research on this subject to date. The aim of this study was to holistically analyze scientific articles published on the subject of Pemphigus between 1980 and 2021 using various statistical and bibliometric methods.
2. Material and methods
2.1. Research strategy
Web of Science Core Collection (WoS by Clarivate Analytics) database was used for literature review. The search process was determined as 1980 to 2021 (publications before 1980 are not available in WoS). All publications containing any of the words related to “Pemphigus” (PV, PF, PNP, Pemphigus vegetans etc) in the title were accessed. The search was conducted in all research areas, but studies published in the Veterinary Sciences, Entomology, Ecology, Agriculture, Zoology, Plant Sciences research field were excluded and not included in the analysis. Repeatability codes (search findings may change depending on different access dates) for researchers to access similar documents: (Title: (“Pemphigus”) Refined by: NOT Research Areas: (Veterinary Sciences or Entomology or Ecology or Agriculture or Zoology or Plant Sciences) Timespan: 1980–2021).
2.2. Statistical analysis
VOSviewer (Version 1.6.16, Leiden University Center for Science and Technology Studies) software was used for bibliometric network visualizations, citation, trend and cluster analyses.[20] Statistical analyses were performed with SPSS (Version 22.0, SPSS Inc., Chicago, IL, License: Hitit University) software. The website (https://app.datawrapper.de) was used to create the world map showing the distribution of publications by country. The Exponential Smoothing estimator was used in Microsoft Office Excel to estimate the number of articles that could be published in the next 5 years based on past publication trends. The normal distribution test of the data was performed with the Kolmogorov-Smirnov test. Correlation analyses between world publication productivity on Pemphigus and some economic development indicators of countries (gross domestic product [GDP], GDP per capita, Human Development Index [HDI]) were analyzed with Spearman correlation coefficient since the data were not normally distributed (data obtained from world bank[21]). P < .05 was accepted for a statistically significant correlation.
This article does not include any studies with human participants or animals by any of the authors. Therefore, ethics committee approval is not required.
3. Results
As a result of the literature review, there were a total of 6516 publications on Pemphigus published in all research areas in the WoS database during the 1980 to 2021 period. A total of 251 publications published in the research fields of Veterinary Sciences, Entomology, Ecology, Agriculture, Zoology and Plant Sciences were excluded and 6265 publications were obtained. Of these publications, 48.4% (n = 3034) were Articles, 24.8% (n = 1553) were Meeting Abstracts, 15.1% (n = 947) were Letters, 4.4% (277) were Review Articles, 1.4% (90) were Proceedings Papers and the rest were in other publication types (Editorial Materials, Notes, Early Access, Book Chapters, News Items, Corrections, Additions, Discussions). Bibliometric analyses were carried out with 3034 articles published in the article category out of a total of 6265 publications. 90.7% (n = 2753) of these articles were published in English and the remainder in other languages (French (n = 96), German (71), Russian (43), Spanish (27), Turkish (21), Polish (9), Portuguese (9), Hungarian (2), Czech (1), Estonian (1), Serbian (1)). The h-index of 3034 articles was 100, average citations per article 21.47, sum of times cited 70007 (without self-citations: 40062). The majority of the articles were indexed in the SCI-expanded (n = 2820, 92.9%). 6.7% (n = 203) were indexed in the Emerging Sources Citation Index (ESCI). In addition, 0.8% (n = 24) of the articles were indexed in the Social Sciences Citation Index (SSCI) (as some studies indexed in the SCI-expanded are also indexed in the SSCI, the number and percentage of articles may be higher than the total number).
3.1. Research areas
After Dermatology (1969, 64.9%), the other top 10 research areas with the most research on Pemphigus were Immunology (273, 8.9%), General Internal Medicine (196, 6.4%), Pathology (131, 4.3%), Dentistry Oral Surgery Medicine (95, 3.1%), Research Experimental Medicine (88, 2.9%), Cell Biology (64, 2.1%), Biochemistry Molecular Biology (56, 1.8%), Pediatrics (52, 1.7%), Infectious Diseases (50, 1.6%), and Pharmacology Pharmacy (41, 1.4%) respectively.
3.2. Development of publications over the years
The distribution of the number of published articles by year is shown in Figure 1. The estimation values of the results of the Exponential Smoothing estimation model used to predict the number of articles that can be published in the next 5 years are shown in Figure 1. According to the estimation model results, it is estimated that 112 (Confidence Interval %: 96–129) articles will be published in 2022 and 126 (CI%: 105–147) articles will be published in 2026 (Fig. 1).
Figure 1.
Distribution of articles published on Pemphigus by yr and predictions for the next 5 yr.
3.3. Active countries
The distribution of the number of articles by world countries is shown in Figure 2. The top 20 countries with the highest number of articles published were USA (831, 27.3%), Japan (402, 13.2%), Germany (221, 7.2%), Italy (206, 6.7%), France (188, 6.1%), Brazil (169, 5.5%), Israel (168, 5.5%), Iran (140, 4.6%), UK (138, 4.1%), India (129, 4.2%), China (112, 3.6%), Turkey (91, 2.9%), Spain (70, 2.3%), Poland (69, 2.2%), Switzerland (57, 1.8%), Australia (46, 1.5%), Netherlands (46, 1.5%), Greece (40, 1.3%), Canada (39, 1.2%), and South Korea (39, 1.2%) (Fig. 2).
Figure 2.
World article productivity density map for all countries that have published articles on Pemphigus and bar graph for the top 20 countries with the most articles.
Cluster analysis was performed among 50 countries that produced at least 2 articles from 83 countries that published articles on Pemphigus and had international cooperation among their authors, and it is shown in Figure 3A. According to the results of the cluster analysis, 8 different clusters were formed for international cooperation. In addition, the total link strength (international cooperation score) scores, which show the cooperation power of 64 countries, were calculated and the international cooperation density map created according to these scores was shown in Figure 3B (Top 20 countries with the highest score: USA = 358, Germany = 210, Japan = 206, Italy = 163, Israel = 143, England (in UK) = 136, France = 128, Switzerland = 117, Netherlands = 105, Australia = 97, Poland = 84, Brazil = 83, Spain = 82, Greece = 71, Iran = 68, Turkey = 64, Croatia = 58, Bulgaria = 55, Hungary = 47, Austria = 43).
Figure 3.
(A) Network visualization map of results of cluster analysis showing international cooperation between countries on Pemphigus. Each color represents a different cluster. As the number of articles published by the countries increases, the size of the circle in which the countries are located increases. The lines show the countries with which they cooperate. (B) Density map showing the intensity of international cooperation of countries on Pemphigus. The strength of international cooperation score increases from blue to red (blue-green-yellow-red).
3.4. Correlation analysis
A statistically significant correlation was found between the number of articles produced by countries on Pemphigus and GDP and GDP per capita values at a moderate level, and a weak correlation with HDI values (respectively, R = 0.670, P < .001; R = 0.661, P < .001, R = 0.450, P < .001).
3.5. Active authors
The top 10 most active authors who published 60 or more articles on Pemphigus were Hashimoto T. (168, 5.5%), Amagai M. (134, 4.4%), Diaz LA. (91, 2.9%), Nishikawa T. (78, 2.5%), Ahmed AR. (76, 2.5%), Anhalt GJ. (65, 2.1%), Joly P. (63, 2%), Daneshpazhooh M. (61, 2%), Hertl M. (61, 2%), and Zillikens D. (60, 1.9%), respectively.
3.6. Active institutions
The top 15 institutions that published the most articles on Pemphigus were Keio University (163, 5.3%), Kurume University (130, 4.2%), Tel Aviv University (107, 3.5%), Sackler Faculty of Medicine (98, 3.2%), Tehran University of Medical Sciences (95, 3.1%), Universidade de Sao Paulo (83, 2.7%), University of Pennsylvania (82, 2.7%), Johns Hopkins University (76, 2.5%), University of California System (76, 2.5%), Assistance Publique Hopitaux de Paris (71, 2.3%), University of Lubeck (67, 2.2%), Harvard University (65, 2.1%), CHU de Rouen (64, 2.1%), University of North Carolina (60, 1.9%), and University of London (57, 1.8%), respectively.
3.7. Active journals
3034 articles on Pemphigus were published in 593 different journals. The first 76 most active journals that contributed the most to the literature that published 6 or more articles from these journals are presented in Table 1. The total number of citations (NC) received by the journals and the average NC per article are presented in Table 1. The citation network visualization map between these journals is presented in Figure 4. When the citation analyses of the journals were evaluated according to the average NC per article they published, the most influential journals were determined as the New England Journal of Medicine (Average citation per article, AC = 246), Lancet (AC = 143), Journal of Cell Biology (AC = 133), Proceedings of the National Academy of Sciences of the United States of America (AC = 131), Journal of Clinical Investigation (AC = 131), Journal of Immunology (AC = 70), Journal of Biological Chemistry (AC = 63), Journal of Investigative Dermatology (AC = 54), and American Journal of Pathology (AC = 53), respectively.
Table 1.
The 76 most active journals that have published 6 or more articles on Pemphigus.
| Journals | RC | C | AC | Journals | RC | C | AC |
|---|---|---|---|---|---|---|---|
| British Journal of Dermatology | 188 | 6028 | 32.1 | Frontiers in Medicine | 14 | 56 | 4.0 |
| Journal of the American Academy of Dermatology | 171 | 6541 | 38.3 | Human Immunology | 14 | 447 | 31.9 |
| Journal of Investigative Dermatology | 143 | 7679 | 53.7 | JAMA Dermatology | 14 | 332 | 23.7 |
| International Journal of Dermatology | 139 | 2669 | 19.2 | Indian Journal of Dermatology | 13 | 43 | 3.3 |
| Archives of Dermatology | 101 | 4199 | 41.6 | Actas Dermo-Sifiliograficas | 12 | 99 | 8.3 |
| Clinical and Experimental Dermatology | 98 | 1284 | 13.1 | American Journal of Pathology | 12 | 637 | 53.1 |
| Journal of the European Academy of Dermatology and Venereology | 80 | 1492 | 18.7 | Australasian Journal of Dermatology | 12 | 71 | 5.9 |
| Annales de Dermatologie et de Venereologie | 71 | 465 | 6.5 | Przeglad Dermatologiczny | 12 | 15 | 1.3 |
| Dermatology | 71 | 1210 | 17.0 | Zeitschrift fur Hautkrankheiten H&G | 12 | 45 | 3.8 |
| European Journal of Dermatology | 58 | 717 | 12.4 | Clinical Immunology | 11 | 368 | 33.5 |
| Journal of Dermatology | 51 | 527 | 10.3 | Journal of Autoimmunity | 11 | 220 | 20.0 |
| Archives of Dermatological Research | 43 | 628 | 14.6 | Journal of Drugs in Dermatology | 11 | 99 | 9.0 |
| Hautarzt | 43 | 202 | 4.7 | New England Journal of Medicine | 11 | 2705 | 245.9 |
| Dermatologica | 42 | 648 | 15.4 | Postepy Dermatologii I Alergologii | 11 | 32 | 2.9 |
| Vestnik Dermatologii I Venerologii | 39 | 50 | 1.3 | Clinical and Experimental Immunology | 10 | 259 | 25.9 |
| Acta Dermato-Venereologica | 38 | 556 | 14.6 | Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics | 10 | 324 | 32.4 |
| Dermatologic Therapy | 37 | 144 | 3.9 | Annals of Dermatology | 9 | 81 | 9.0 |
| Experimental Dermatology | 36 | 632 | 17.6 | Dermatologica Sinica | 9 | 13 | 1.4 |
| Journal of Cutaneous Pathology | 34 | 354 | 10.4 | Giornale Italiano di Dermatologia e Venereologia | 9 | 45 | 5.0 |
| Cutis | 31 | 282 | 9.1 | Plos One | 9 | 318 | 35.3 |
| Frontiers in Immunology | 31 | 268 | 8.6 | Proceedings of the National Academy of Sciences of the United States of America | 9 | 1182 | 131.3 |
| Anais Brasileiros de Dermatologia | 30 | 223 | 7.4 | Journal of Clinical Immunology | 8 | 212 | 26.5 |
| Pediatric Dermatology | 27 | 266 | 9.9 | International Immunopharmacology | 8 | 102 | 12.8 |
| Journal of Immunology | 26 | 1825 | 70.2 | Acta Cytologica | 7 | 82 | 11.7 |
| Indian Journal of Dermatology Venereology & Leprology | 26 | 267 | 10.3 | Cureus | 7 | 1 | 0.1 |
| Autoimmunity | 25 | 524 | 21.0 | Dermatology Practical & Conceptual | 7 | 5 | 0.7 |
| Journal of Dermatological Science | 25 | 555 | 22.2 | Diagnostic Cytopathology | 7 | 68 | 9.7 |
| Journal of Clinical Investigation | 23 | 3008 | 130.8 | Genes and Immunity | 7 | 155 | 22.1 |
| Journal of Dermatological Treatment | 23 | 129 | 5.6 | Journal of Cutaneous Medicine and Surgery | 7 | 55 | 7.9 |
| Clinics in Dermatology | 22 | 893 | 40.6 | Oral Diseases | 7 | 65 | 9.3 |
| Journal of Oral Pathology & Medicine | 21 | 216 | 10.3 | American Journal of Clinical Dermatology | 6 | 81 | 13.5 |
| American Journal of Dermatopathology | 20 | 147 | 7.4 | Autoimmunity Reviews | 6 | 212 | 35.3 |
| Dermatologic Clinics | 20 | 457 | 22.9 | Chinese Medical Journal | 6 | 37 | 6.2 |
| Journal of Biological Chemistry | 20 | 1268 | 63.4 | Clinical Case Reports | 6 | 7 | 1.2 |
| Turkderm-Turkish Archives of Dermatology and Venerology | 17 | 17 | 1.0 | Journal of Cell Biology | 6 | 799 | 133.2 |
| Acta Dermatovenerologica Croatica | 16 | 55 | 3.4 | Lancet | 6 | 856 | 142.7 |
| Journal der Deutschen Dermatologischen Gesellschaft | 16 | 368 | 23.0 | Mediators of Inflammation | 6 | 111 | 18.5 |
| Tissue Antigens | 16 | 548 | 34.3 | Immunology | 6 | 51 | 8.5 |
AC = Average citation per document, C = Record count, C = Number of citations.
Figure 4.
Network visualization map for analysis of citations per article of active journals that publish the most articles on Pemphigus. As the number of articles published by the journals increases, the size of the circle in which the journals are located increases. The average number of citations per article by journals increases from blue to red (blue-green-yellow-red).
3.8. Citation analysis
Among the 3034 articles published on Pemphigus, the first 25 articles with the highest NC (over 200 citations) according to the total NC are presented in Table 2. In the last column of Table 2, the average NC the articles received per year is given.
Table 2.
The top 25 most cited articles on Pemphigus by total number of citations.
| No | Article | Author | Journal | PY | TC | AC |
|---|---|---|---|---|---|---|
| 1 | Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion | Amagai, M. et al[1] | Cell | 1991 | 769 | 24.03 |
| 2 | Paraneoplastic Pemphigus - an autoimmune mucocutaneous disease associated with neoplasia | Anhalt, GJ. et al[6] | New England Journal of Medicine | 1990 | 744 | 22.55 |
| 3 | Induction of Pemphigus in neonatal mice by passive transfer of igg from patients with the disease | Anhalt, GJ. et al[22] | New England Journal of Medicine | 1982 | 509 | 12.41 |
| 4 | Characterization of autoantibodies in Pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins | Ishii, K. et al[23] | Journal of Immunology | 1997 | 386 | 14.85 |
| 5 | Bullous pemphigoid and pemphigus vulgaris - incidence and mortality in the UK: population based cohort study | Langan, SM. et al[12] | BMJ-British Medical Journal | 2008 | 379 | 25.27 |
| 6 | Consensus statement on definitions of disease, end points, and therapeutic response for Pemphigus | Murrell, DE. et al[10] | Journal of the American Academy of Dermatology | 2008 | 344 | 22.93 |
| 7 | Targeted disruption of the pemphigus vulgaris antigen (Desmoglein 3) gene in mice causes loss of keratinocyte cell adhesion with a phenotype similar to pemphigus vulgaris | Koch, PJ. et al | Journal of Cell Biology | 1997 | 339 | 13.04 |
| 8 | Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin | Ahmed, A. et al[8] | New England Journal of Medicine | 2006 | 333 | 19.59 |
| 9 | Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris | Mahoney, MG. et al | Journal of Clinical Investigation | 1999 | 328 | 13.67 |
| 10 | A single cycle of rituximab for the treatment of severe Pemphigus | Joly, P. et al[9] | New England Journal of Medicine | 2007 | 313 | 19.56 |
| 11 | The clinical phenotype of Pemphigus is defined by the anti-desmoglein autoantibody profile | Amagai, M. et al | Journal of the American Academy of Dermatology | 1999 | 290 | 12.08 |
| 12 | Usefulness of enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis of Pemphigus | Amagai, M. et al | British Journal of Dermatology | 1999 | 279 | 11.63 |
| 13 | Pemphigus | Bystryn, JC and Rudolph, JL[2] | Lancet | 2005 | 275 | 15.28 |
| 14 | Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic | Amagai, M. et al | Journal of Clinical Investigation | 1992 | 273 | 8.81 |
| 15 | Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (dsg3) produced by baculovirus | Amagai, M. et al | Journal of Clinical Investigation | 1994 | 266 | 9.17 |
| 16 | Detection of pemphigus vulgaris and pemphigus foliaceus antigens by immunoblot analysis using different antigen sources | Hashimoto, T. et al | Journal of Investigative Dermatology | 1990 | 255 | 7.73 |
| 17 | First-line rituximab combined with short-term prednisone vs prednisone alone for the treatment of Pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomized trial | Joly, P. et al[24] | Lancet | 2017 | 242 | 40.33 |
| 18 | Desmoglein 4 in hair follicle differentiation and epidermal adhesion: Evidence from inherited hypotrichosis and acquired pemphigus vulgaris | Kljuic, A. et al | Cell | 2003 | 239 | 11.95 |
| 19 | Antibodies against desmoglein 3 (Pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic Pemphigus and cause acantholysis in vivo in neonatal mice | Amagai, M. et al | Journal of Clinical Investigation | 1998 | 234 | 9.36 |
| 20 | Demonstration of an adhering-junction molecule (plakoglobin) in the auto-antigens of pemphigus foliaceus and pemphigus vulgaris | Korman, NJ. et al | New England Journal of Medicine | 1989 | 227 | 6.68 |
| 21 | The pathogenic effect of igg4 autoantibodies in endemic pemphigus foliaceus (fogo selvagem) | Rock, B. et al | New England Journal of Medicine | 1989 | 224 | 6.59 |
| 22 | Induction of Pemphigus phenotype by a mouse monoclonal antibody against the amino-terminal adhesive interface of desmoglein 3 | Tsunoda, K. et al | Journal of Immunology | 2003 | 223 | 11.15 |
| 23 | Anti-cell surface Pemphigus autoantibody stimulates plasminogen-activator activity of human epidermal-cells - a mechanism for the loss of epidermal cohesion and blister formation | Hashimoto, K. et al | Journal of Experimental Medicine | 1983 | 222 | 5.55 |
| 24 | Distinction between epidermal antigens binding pemphigus vulgaris and pemphigus foliaceus autoantibodies | Stanley, JR. et al | Journal of Clinical Investigation | 1984 | 215 | 5.51 |
| 25 | Antigen-specific immunoadsorption of pathogenic autoantibodies in pemphigus foliaceus | Amagai, M. et al | Journal of Investigative Dermatology | 1995 | 210 | 7.5 |
AC = average citations per year, PY = publication year, TC = total citation.
3.9. Co-citation analysis
There were a total of 28271 studies cited in the references section of all 3034 articles published on Pemphigus. Among these studies, the 5 most influential studies with the most co-citations (more than 200 citations) were Amagai et al (1991) (NC = 358), Anhalt et al (1990) (NC = 288), Anhalt et al (1982) (NC = 239), Ishii (1997) et al (NC = 213), and Murrell et al (2008) (NC = 204), respectively.[1,6,10,22,23]
3.10. Trend topics and co-occurrence analysis
2701 different keywords were used in all of the 3034 articles published on Pemphigus. Among these keywords, 100 different keywords used in at least 7 different articles are shown in Table 3. The most studied topics from past to present were PV, PF, autoimmunity, rituximab, PNP, desmoglein-desmoglein 3-desmoglein 1, autoantibodies, acantholysis, autoantibody, treatment, autoimmune disease, desmosome, ELISA, and immunofluorescence, respectively.
Table 3.
The 100 most frequently used keywords in articles on Pemphigus.
| Keywords | Number of uses | Keywords | Number of uses | Keywords | Number of uses |
|---|---|---|---|---|---|
| Pemphigus | 544 | Castleman disease | 19 | bullous diseases | 9 |
| pemphigus vulgaris | 508 | IGA Pemphigus | 18 | dermatology | 9 |
| pemphigus foliaceus | 142 | keratinocytes | 18 | envoplakin | 9 |
| autoimmunity | 116 | azathioprine | 17 | epitope | 9 |
| rituximab | 112 | cytokines | 17 | immunoblotting | 9 |
| paraneoplastic Pemphigus | 107 | diagnosis | 17 | oral mucosa | 9 |
| desmoglein | 102 | remission | 17 | Pemphigus herpetiformis | 9 |
| autoantibodies | 70 | cyclophosphamide | 16 | psoriasis | 9 |
| acantholysis | 50 | dapsone | 16 | quality of life | 9 |
| desmoglein 3 | 49 | autoimmune bullous diseases | 14 | skin diseases | 9 |
| autoantibody | 44 | direct immunofluorescence | 14 | vesiculobullous | 9 |
| treatment | 43 | intravenous immunoglobulin | 14 | blistering disease | 8 |
| autoimmune disease | 41 | prognosis | 14 | desmocollin | 8 |
| desmosome | 41 | bronchiolitis obliterans | 13 | drug-induced Pemphigus | 8 |
| desmoglein 1 | 37 | endemic pemphigus foliaceus | 13 | herpes simplex virus | 8 |
| ELISA | 36 | indirect immunofluorescence | 13 | immunoadsorption | 8 |
| immunofluorescence | 31 | mycophenolate mofetil | 13 | Immunology | 8 |
| desmogleins | 28 | castleman disease | 12 | mouse model | 8 |
| autoimmune | 27 | HLA | 11 | Pemphigus erythematosus | 8 |
| bullous pemphigoid | 27 | human leukocyte antigen | 11 | periplakin | 8 |
| corticosteroids | 26 | polymorphism | 11 | pregnancy | 8 |
| enzyme-linked immunosorbent assay | 26 | pulse therapy | 11 | thymoma | 8 |
| epidemiology | 26 | cell adhesion | 10 | autoantigen | 7 |
| apoptosis | 24 | immunohistochemistry | 10 | chronic lymphocytic leukemia | 7 |
| desmosomes | 23 | immunosuppression | 10 | dexamethasone | 7 |
| Pemphigus vegetans | 23 | keratinocyte | 10 | disease severity | 7 |
| therapy | 23 | lymphoma | 10 | genetic susceptibility | 7 |
| pemphigoid | 22 | mortality | 10 | IGA | 7 |
| autoimmune bullous disease | 21 | oral Pemphigus | 10 | methotrexate | 7 |
| autoimmune diseases | 21 | plasmapheresis | 10 | pathogenesis | 7 |
| bullous disease | 21 | polymerase chain reaction | 10 | Pemphigus foliaceous | 7 |
| cadherin | 21 | relapse | 10 | wound healing | 7 |
| skin | 21 | systemic lupus erythematosus | 10 | ||
| fogo selvagem | 20 | blister | 9 |
The cluster network visualization map showing the results of cluster analysis performed between these keywords is shown in Figure 5. As a result of cluster analysis, it was seen that Pemphigus topics formed 9 different main clusters (General topics in which the clusters are divided: 1: desmoglein (red), 2: PNP – Pemphigus types- desmosome (green), 3: desmoglein 1 ve 3-autoimmunity (blue), 4: treatment-rituximab (yellow), 5: acantholysis-apoptosis (purple), 6: quality of life-remission-relapse (turquoise), 7: autoantibodies (orange), 8: epidemiology-mortality (brown), 9: corticosteroids (pink).
Figure 5.
Network visualization map for cluster analysis based on keyword analysis performed to identify clustering of Pemphigus. Each color represents a different cluster. Keywords in the same cluster are of the same color. The size of the circle represents the number of times the keyword has been used.
The trend network visualization map performed to identify trend topics is shown in Figure 6. According to the results of the analysis performed to determine the trend topics, it was determined that the trend keywords studied in recent years are rituximab, azathioprine, mortality, quality of life, remission, relapse, psoriasis, skin diseases, vesiculobullous, disease severity, Immunology, autoimmune bullous disease, Pemphigus herpetiformis, wound healing, and intravenous immunoglobulin.
Figure 6.
Network visualization map based on keyword analysis to identify past and current trends on Pemphigus. In the indicator given in the lower right corner of the figure, the topicality of the article increases from blue to red (blue-green-yellow-red). The size of the circle represents the number of times the keyword has been used.
The citation network visualization map performed to reveal the most cited topics is shown in Figure 7. It was determined that the most cited keywords were desmosomes, autoantibody, therapy, diagnosis, cadherin, cell adhesion, autoantigen, autoimmunity, desmoglein, keratinocyte, and enzyme-linked immunosorbent assay.
Figure 7.
Network visualization map based on keyword analysis performed to identify the most cited topics on Pemphigus. In the indicator given in the lower right corner of the figure, the number of citations received by the subject increases from blue to red (blue-green-yellow-red). The size of the circle represents how many times the keyword is used.
4. Discussion
The number of articles published on the subject of Pemphigus was between 35 and 56 (mean 45) in the period 1980 to 1996, between 57 and 75 (mean 67) for 1997 to 2005, between 81 and 114 (mean 97) for 2006 to 2018, and between 125 and 138 (mean 131) for 2019 to 2021. When the number of articles that could be published in the next 5 years was evaluated, obtained with Exponential Smoothing estimation based on time series taking seasonal correction into consideration, it can be said that the number of articles on the subject of Pemphigus will continue to increase.
When the distribution of publications of countries was examined, 16 of the 20 most active countries providing the greatest contribution to the literature were determined to be developed countries. The other 4 of these most active countries are classified as developing countries but are countries with large economies (Iran, India, China, Turkey). When the correlation analysis results were evaluated, there was determined to be a moderate level correlation between productivity of Pemphigus articles and GDP and GDP per capita values, and a weak level correlation with HDI values, showing that the size of the economy and level of development of a country were effective factors in publication productivity. The density map formed according to the total collaboration scores between countries was evaluated, and the 10 countries with the most intense collaboration were determined to be the USA, Germany, Japan, Italy, Israel, England (in UK), France, Switzerland, Netherlands, and Australia, respectively.
When author collaborations have been examined in bibliometric studies in literature, geographical proximity has been seen to be effective in international collaboration of article production.[16,17] However, in the current study, it was seen that in author collaboration on the subject of Pemphigus, international collaboration was not based on geographical proximity, but global collaboration was more common (Austria, Chile, Croatia, Czech Republic, Egypt, Iran, Japan, Poland, South Korea, Turkey, Indonesia, Netherlands), (Australia, Canada, Denmark, India, Israel, Singapore, Spain), (Belgium, Brazil, France, Hungary, Morocco, Tunisia, United Arab Emirates), (Colombia, Norway, Peru, Sweden, Thailand, USA), (Bulgaria, England (in UK), Portugal, Saudi Arabia, Wales (in UK)), (Greece, China, Russia, South Africa, Taiwan), (Italy, Mexico, Scotland (in UK), Switzerland), (Germany, Romania, Slovakia).
The journals that published the most articles on Pemphigus are presented in the results section. We can suggest that authors who are in the research process or want to publish on Pemphigus should consider the journals presented in Table 1, primarily these journals. We can also recommend that researchers who want to have more impact on their work to be published should primarily consider influential journals according to their citation numbers.
The analyzed articles were evaluated according to the total citation count (CC) received. The study with the highest NC was “Autoantibodies against a novel epithelial cadherin in Pemphigus vulgaris, a disease of cell-adhesion,” published in Cell by Amagai et al (1991).[1] This was followed by “Paraneoplastic Pemphigus - an autoimmune mucocutaneous disease associated with neoplasia,” published in the New England Journal of Medicine by Anhalt et al (1990),[6] “Induction of Pemphigus in neonatal mice by passive transfer of IgG from patients with the disease” published in the New England Journal of Medicine by Anhalt et al (1982),[22] “Characterization of autoantibodies in Pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins” published in the Journal of Immunology by Ishii et al (1997),[23] and “Bullous pemphigoid and PV - incidence and mortality in the UK: population based cohort study” published in the British Medical Journal by Langan et al (2008).[12]
The analyzed articles were also evaluated according to the mean NC received per year. The most effective article in this respect was “First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of Pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomized trial” published in the Lancet by Joly et al (2017),[24] followed by the consensus statements on Pemphigus of Murrell et al (2008).[10] The third most effective study was an article by Kasperkiewicz et al (2008),[3] the fourth was by Langan et al (2008)[12] and the fifth was by Amagai et al (1991).[1] According to the co-CCs of all the articles analyzed, the most effective articles were determined to be by Amagai et al (1991), Anhalt et al (1990), Anhalt et al (1982), Ishii (1997) et al (NC = 213) and Murrell et al (2008).[1,6,10,22,23] It can therefore be recommended that dermatologists, other clinicians, and researchers interested in this subject should read these articles first.
When evaluating the findings of keyword analysis in Pemphigus research from the past to the present, a wide spectrum of key themes has emerged, focusing on various aspects such as different types of disease, immune system reactions, treatment methods, cellular structures, and analysis techniques used for diagnosis. These subjects have been extensively examined to provide a comprehensive understanding of the origins, progression, and effective treatments of the disease. Furthermore, recent research trends indicated by keyword analysis have centered on the management and effects of autoimmune bullous diseases, addressing topics including treatment options, disease severity, mortality rates, patients’ quality of life, remission, and relapse cycles. Additionally, studies related to vesiculobullous conditions associated with other dermatological diseases, the immunological foundations of specific conditions like Pemphigus herpetiformis, wound healing processes, and research on treatment methods such as intravenous immunoglobulin, have seen an increase. Encompassing a wide array of autoimmune bullous diseases, these topics have garnered attention in both clinical and research domains.
Pemphigus typically initiates in middle to later ages but can occur at any age, albeit rarely manifesting during childhood.[25] In Germany, the prevalence of autoimmune bullous diseases in the pediatric population under 18 years was estimated at 101.1 per million children (approximately 1351 patients) in 2015. The highest prevalence among all autoimmune bullous diseases was observed for PV (30.5 per million children), followed by linear IGA disease (24.5 per million children) and bullous pemphigoid (4.9 per million children).[26] Jelti et al (2019) observed an increase in the incidence of Pemphigus with age in France, with the highest incidence occurring in individuals aged 80 and above.[27] The age of onset for the most common type of Pemphigus, PV, constituting 70% of cases, ranged between 36.5 years in Kuwait to 72.4 years in Bulgaria.[28]
A recent prevalence study conducted in the USA with 1795 Pemphigus patients reported an increasing prevalence in older age groups. The overall standardized prevalence was reported to be similar between women (5.7 per million; 95%CI, 5.3–6.0) and men (4.6 per million; 95%CI, 4.3–5.0) and across racial groups.[29] While the disease can occur in both genders, some studies suggest a slightly higher prevalence among females than males. Finland reported the lowest female-to-male sex ratio at 1.01, whereas Kuwait reported the highest at 5.75. The global average female-to-male ratio was reported as 1.87.[30]
Pemphigus epidemiology displays variations among racial populations worldwide, being more prevalent in certain ethnic groups. However, the disease can manifest in any ethnic group globally. The higher frequency of autoimmune bullous diseases in certain ethnic groups such as Pemphigus in Ashkenazi Jews or PF in specific regions of Brazil has been associated respectively with genetic and environmental factors. However, conclusive evidence regarding why certain ethnic groups experience a higher incidence remains elusive.[11]
Pemphigus treatment is typically carried out with immunosuppressive drugs such as corticosteroids and other immunosuppressive agents. The goal of treatment is to reduce disease severity, control lesions, and achieve remission.[31,32] However, there might be some variations in response to Pemphigus treatment among individuals from different ethnic groups. The underlying reasons for these variations are not entirely clear, but it is believed that genetic and environmental factors can influence the response to treatment. Some studies suggest that different genetic variations can affect individuals’ immune system responses, hence altering their responses to treatment. Additionally, various ethnic groups’ exposure to different environmental factors and lifestyles may impact their responses to treatment. Nevertheless, research in this area is ongoing, and there is currently no definitive consensus regarding responses to Pemphigus treatment among individuals from diverse ethnic backgrounds.[3,32]
As a result of a scan of literature on Pemphigus, no comprehensive bibliometric study was found on this subject. A systematic review on the subject of Pemphigus has only been conducted by Yang et al (2021), in which the 100 studies on Pemphigus that received the most citations between 2011 and 2020 were examined.[33] The current study can be said to be more comprehensive than that study both in terms of the period examined and the number of articles analyzed. In addition to citation analyses, the current study used several other statistical approaches such as trend keyword analysis, cluster analysis, and correlation analyses.
A limitation of this study can be said to be that only the WoS database was examined in the literature scan. However, the citation and co-citation analyses were conducted using the PubMed database.[17,34] Moreover, compared to the Scopus database, the WoS database indexes articles published in journals with more impact (only journals scanned in the SCI-expanded, ESCI and SSCI index).[17,34]
5. Conclusion
In this comprehensive bibliometric study on the subject of Pemphigus, the information is presented from the statistical analysis of 3034 articles published from 1980 to 2022. According to the results of the analysis to determine trend subjects, the subject most studied in recent years was determined to be rituximab, a drug used in Pemphigus treatment. Other trend subjects being studied are azathioprine drug used in treatment, intravenous immunoglobulin treatment, quality of life and mortality rates of patients with Pemphigus, Pemphigus herpetiformis, and wound healing. The existing research on Pemphigus addresses a broad spectrum of subjects both in dermatology clinical research and in the fields of autoimmunity and cell adhesion. According to the findings of global productivity on the subject of Pemphigus obtained in this study, there is a need to support Pemphigus research in economically less developed countries. This study can be considered to be a useful resource for dermatologists and other scientists in respect of the global output on the subject of Pemphigus.
Authors contributions
Conceptualization: Aynure Öztekin, Coşkun Öztekin.
Data curation: Aynure Öztekin, Coşkun Öztekin.
Formal analysis: Aynure Öztekin, Coşkun Öztekin.
Investigation: Aynure Öztekin, Coşkun Öztekin.
Methodology: Aynure Öztekin, Coşkun Öztekin.
Resources: Aynure Öztekin, Coşkun Öztekin.
Software: Aynure Öztekin, Coşkun Öztekin.
Supervision: Aynure Öztekin.
Validation: Aynure Öztekin.
Visualization: Aynure Öztekin, Coşkun Öztekin.
Writing – original draft: Aynure Öztekin, Coşkun Öztekin.
Writing – review & editing: Aynure Öztekin, Coşkun Öztekin.
Abbreviations:
- AC
- average citation per article
- CC
- citation count
- CI
- confidence interval
- GDP
- gross domestic product
- HDI
- human development index
- NC
- number of citations
- PF
- pemphigus foliaceus
- PNP
- paraneoplastic Pemphigus
- PV
- pemphigus vulgaris
- UK
- United Kingdom
- USA
- United States of America
- WoS
- web of science
The authors have no funding and conflicts of interest to disclose.
This article does not contain any studies with human participants or animals performed by any of the authors.
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
How to cite this article: Öztekin A, Öztekin C. The evolution of Pemphigus publications: A bibliometric analysis with research trends and global productivity. Medicine 2024;103:18(e38047).
References
- [1].Amagai M, Klaus-Kovtun V, Stanley JR. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell. 1991;67:869–77. [DOI] [PubMed] [Google Scholar]
- [2].Bystryn JC, Rudolph JL. Pemphigus. Lancet. 2005;366:61–73. [DOI] [PubMed] [Google Scholar]
- [3].Kasperkiewicz M, Ellebrecht CT, Takahashi H, et al. Pemphigus. Nat Rev Dis Primers. 2017;3:1–18. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [4].Joly P, Horvath B, Patsatsi Α, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the European academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol. 2020;34:1900–13. [DOI] [PubMed] [Google Scholar]
- [5].Abreu-Velez AM, Calle-Isaza J, Howard MS. Autoimmune epidermal blistering diseases. Our Dermatol Online. 2013;4:631–46. [Google Scholar]
- [6].Anhalt GJ, Kim S, Stanley JR, et al. Paraneoplastic pemphigus - an autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med. 1990;323:1729–35. [DOI] [PubMed] [Google Scholar]
- [7].Rashid M. Pemphigus pain: a review on management. Clin J Pain. 2008;24:734–5. [DOI] [PubMed] [Google Scholar]
- [8].Ahmed AR, Spigelman Z, Cavacini LA, et al. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006;355:1772–9. [DOI] [PubMed] [Google Scholar]
- [9].Joly P, Mouquet H, Roujeau JC, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007;357:545–52. [DOI] [PubMed] [Google Scholar]
- [10].Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol. 2008;58:1043–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [11].Alpsoy E, Akman-Karakas A, Uzun S. Geographic variations in epidemiology of two autoimmune bullous diseases: pemphigus and bullous pemphigoid. Arch Dermatol Res. 2015;307:291–8. [DOI] [PubMed] [Google Scholar]
- [12].Langan SM, Smeeth L, Hubbard R, et al. Bullous pemphigoid and pemphigus vulgaris - incidence and mortality in the UK: population based cohort study. BMJ. 2008;337:a180. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [13].Bertram F, Brocker EB, Zillikens D, et al. Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges. 2009;7:434–40. [DOI] [PubMed] [Google Scholar]
- [14].Michailidou EZ, Belazi MA, Markopoulos AK, et al. Epidemiologic survey of pemphigus vulgaris with oral manifestations in northern Greece: retrospective study of 129 patients. Int J Dermatol. 2007;46:356–61. [DOI] [PubMed] [Google Scholar]
- [15].Pisanti S, Sharav Y, Kaufman E, et al. Pemphigus vulgaris: incidence in Jews of different ethnic groups, according to age, sex, and initial lesion. Oral Surg Oral Med Oral Pathol. 1974;38:382–7. [DOI] [PubMed] [Google Scholar]
- [16].Kiraz M, Demir E, Özdemir O. An international bibliometric study of scientific articles on intracranial aneurysms. Neuroradiol J. 2021;34:482–93. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [17].Kiraz S, Demir E. Global scientific outputs of schizophrenia publications from 1975 to 2020: a bibliometric analysis. Psychiatr Q. 2021;92:1725–44. [DOI] [PubMed] [Google Scholar]
- [18].Şenel E, Demir E, Alkan RM. Bibliometric analysis on global Behçet disease publications during 1980–2014: is there a Silk Road in the literature? J Eur Acad Dermatol Venereol. 2017;31:518–22. [DOI] [PubMed] [Google Scholar]
- [19].Rencz F, Gulacsi L, Tamasi B, et al. Health-related quality of life and its determinants in pemphigus: a systematic review and meta-analysis. Br J Dermatol. 2015;173:1076–80. [DOI] [PubMed] [Google Scholar]
- [20].Van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84:523–38. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [21].The World Bank. World Development Indicators. https://data.worldbank.org/indicator/NY.GDP.MKTP.CD. Accessed March 1, 2022.
- [22].Anhalt GJ, Labib RS, Voorhees JJ, et al. Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med. 1982;306:1189–96. [DOI] [PubMed] [Google Scholar]
- [23].Ishii K, Amagai M, Hall RP, et al. Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol. 1997;159:2010–7. [PubMed] [Google Scholar]
- [24].Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389:2031–40. [DOI] [PubMed] [Google Scholar]
- [25].Murrell DF, Peña S, Joly P, et al. Diagnosis and management of pemphigus: recommendations of an international panel of experts. J Am Acad Dermatol. 2020;82:575–85.e1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [26].Hübner F, König IR, Holtsche MM, et al. Prevalence and age distribution of pemphigus and pemphigoid diseases among paediatric patients in Germany. J Eur Acad Dermatol Venereol. 2020;34:2600–5. [DOI] [PubMed] [Google Scholar]
- [27].Jelti L, Cordel N, Gillibert A, et al. Incidence and mortality of pemphigus in France. J Invest Dermatol. 2019;139:469–73. [DOI] [PubMed] [Google Scholar]
- [28].Kridin K. Pemphigus group: overview, epidemiology, mortality, and comorbidities. Immunol Res. 2018;66:255–70. [DOI] [PubMed] [Google Scholar]
- [29].Wertenteil S, Garg A, Strunk A, et al. Prevalence estimates for pemphigus in the United States: a sex- and age-adjusted population analysis. JAMA Dermatol. 2019;155:627–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [30].Rosi-Schumacher M, Baker J, Waris J, et al. Worldwide epidemiologic factors in pemphigus vulgaris and bullous pemphigoid. Front Immunol. 2023;14:1159351. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [31].Zhao W, Wang J, Zhu H, et al. Comparison of guidelines for management of pemphigus: a review of systemic corticosteroids, rituximab, and other immunosuppressive therapies. Clin Rev Allergy Immunol. 2021;61:351–62. [DOI] [PubMed] [Google Scholar]
- [32].Lim YL, Bohelay G, Hanakawa S, et al. autoimmune pemphigus: latest advances and emerging therapies. Front Mol Biosci. 2022;8:808536. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [33].Yang TY, Chen CH, Chien TW, et al. Predicting the number of article citations on the topic of pemphigus vulgaris with the 100 top-cited articles since 2011: a protocol for systematic review and meta-analysis. Medicine (Baltimore). 2021;100:e26806. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [34].Demir E, Yaşar E, Özkoçak V, et al. The evolution of the field of legal medicine: a holistic investigation of global outputs with bibliometric analysis. J Forensic Leg Med. 2020;69:101885. [DOI] [PubMed] [Google Scholar]







